Anti-Inflammatory Effects Of Fargesin On Chemically Induced Inflammatory Bowel Disease In Mice

Fargesin is a bioactive lignan from Flos Magnoliae, an herb widely used in the treatment of allergic rhinitis, sinusitis, and headache in Asia. We sought to investigate whether fargesin ameliorates experimental inflammatory bowel disease (IBD) in mice. Oral administration of fargesin significantly attenuated the symptoms of dextran sulfate sodium (DSS)-induced colitis in mice by decreasing the inflammatory infiltration and myeloperoxidase (MPO) activity, reducing tumor necrosis factor (TNF)-alpha secretion, and inhibiting nitric oxide (NO) production in colitis mice. The degradation of inhibitory kappa B alpha (I kappa B alpha), phosphorylation of p65, and mRNA expression of nuclear factor kappa B (NF-kappa B) target genes were inhibited by fargesin treatment in the colon of the colitis mice. In vitro, fargesin blocked the nuclear translocation of p-p65, downregulated the protein levels of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), and dose-dependently inhibited the activity of NF-kappa B-luciferase in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. Taken together, for the first time, the current study demonstrated the anti-inflammatory effects of fargesin on chemically induced IBD might be associated with NF-kappa B signaling suppression. The findings may contribute to the development of therapies for human IBD by using fargesin or its derivatives.